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Abstract
The JAK2 V617F mutation present in over 95% of Polycythemia Vera patients and in 50% of Essential Thrombocythemia and
Primary Myelofibrosis patients renders the kinase constitutively active. In the absence of a three-dimensional structure for
the full-length protein, the mechanism of activation of JAK2 V617F has remained elusive. In this study, we used functional
mutagenesis to investigate the involvement of the JH2 aC helix in the constitutive activation of JAK2 V617F. We show that
residue F595, located in the middle of the aC helix of JH2, is indispensable for the constitutive activity of JAK2 V617F.
Mutation of F595 to Ala, Lys, Val or Ile significantly decreases the constitutive activity of JAK2 V617F, but F595W and F595Y
are able to restore it, implying an aromaticity requirement at position 595. Substitution of F595 to Ala was also able to
decrease the constitutive activity of two other JAK2 mutants, T875N and R683G, as well as JAK2 K539L, albeit to a lower
extent. In contrast, the F595 mutants are activated by erythropoietin-bound EpoR. We also explored the relationship
between the dimeric conformation of EpoR and several JAK2 mutants. Since residue F595 is crucial to the constitutive
activation of JAK2 V617F but not to initiation of JAK2 activation by cytokines, we suggest that small molecules that target
the region around this residue might specifically block oncogenic JAK2 and spare JAK2 wild-type.
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Introduction
JAK2 belongs to the Janus kinases (JAKs) family of non-
receptor tyrosine kinases, crucial to blood formation and
immune responses. JAK2 plays a role in downstream signaling
pathways such as the JAK/STAT pathway, involved in cytokine
signaling. Members of the JAK family possess seven defined
regions of conserved homology denoted JAK homology (JH)
domains 1-7 [1]. JH5-7 make up the amino terminus of JAKs
and contain a predicted FERM (Band-4.1, ezrin, radixin and
moesin)-like motif [2], important in association of JAKs to their
receptors and in some cases in receptor cell-surface expression
[3,4,5]. Although the JH3-4 domains display some homology to
SH2 domains, their function remains ambiguous [6]. The
carboxyl terminus is composed of JH1 and JH2 and contains the
kinase and pseudokinase domains, respectively [7]. The JAK2
JH1 domain includes all the features of a catalytic tyrosine
kinase, while the JH2 domain, though highly sequence-
homologous to JH1, lacks several elements conferring catalytic
activity. Interestingly, early functional studies showed an
inhibitory effect of pseudokinase domain on the kinase domain
of JAK2 [8,9].
While currently there is no three-dimensional structure for any
full-length Janus kinase, the crystal structures of JAK2, JAK1 and
JAK3 kinase domains in isolation have been solved in complex with
specific inhibitors [10,11,12]. The JAK2 kinase domain exhibits a
typical bilobar arrangement, with a secondary structure profile very
similar to other solved kinase domains [13,14]. The N-terminal lobe
of JAK2 is composed of b-strands and includes a single helix, aC,
while the C-terminal lobe is mostly helical [10,12].
A single acquired somatic mutation in the pseudokinase domain
of JAK2, in the form of a substitution of Val for Phe at position
617, is at the base of .95% Polycythemia Vera (PV) patients and
50–60% of patients with Essential Thrombocythemia (ET) and
Primitive Myelofibrosis (PMF) [15,16,17,18]. The V617F muta-
tion induces constitutive tyrosine phosphorylation of JAK2 and
STAT5 and renders Ba/F3 cells that express the erythropoietin
receptor (EpoR) cytokine-independent.
Despite a plethora of recent reports describing the contribution
of V617F to different pathologies, a comprehensive mechanism of
activation of this mutation has yet to be proposed. In this work we
explore the role of the pseudokinase domain helix C in the
constitutive activation of JAK2 V617F by focusing on residue
F595, predicted to be located in the middle of the helix.
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11157Results
A predicted interaction between residue 617 and the JH2
aC helix
The structure of a complex of the kinase (JH1) and
pseudokinase (JH2) domains has not been solved for any JAK
family member. Since residue V617 is located in the pseudokinase
domain of JAK2, this lack of information has hindered a detailed
understanding of the mechanism of activation of JAK2 V617F. A
homology model of the kinase and pseudokinase domains of
JAK2, suggests an overall 3D structure of the JH2 domain, similar
to that of JH1 and other solved kinase domains, as well as a
potential face-to-face arrangement of the two domains [19]. This
model places residue V617 in a loop connecting b-strands 4 and 5
in the N-terminal lobe of JH2 and in close proximity to the JH2
aC helix. The b4/b5 loop as well as the aC-b4 loop that precedes
b4, were previously shown to play regulatory roles in the
mechanisms of Src and Abl tyrosine kinases through interactions
with the kinase domain aC helix in the N-terminal lobe [20,21]. A
specific conformation of the kinase domain aC helix is essential for
kinase activation [22] and members of the kinase family have
evolved diverse ways to influence the position of their aC helices as
a means to affect activity [13,14,23].
Given the proximity of the V617F mutation to the JH2 aC
helix, we sought to identify residues in the JH2 aC helix, which
could have a potential effect on the overall position and
conformation of this helix. Inspection of the crystal structures of
several kinases revealed that the closest residue in space to the
homologous V617 position frequently resided in the middle of the
aC helix, on the face of the helix facing the homologous V617
residue (Figure 1A and B). In JAK2, this residue corresponds to
F595 in the JH2 aC helix (Figure 1C). The homologous residues of
position 595 are generally represented by large, hydrophobic
residues pointing to preservation of the hydropathy profile at this
position, and suggesting a mechanistic role for those residues in
kinase function (Figure 1A).
Constitutive activity of JAK2 V617F requires F595
We hypothesized that when V617 is mutated to Phe, this could
influence the neighboring F595, affecting the conformation of the
aC helix of JH2 in a specific manner, that would promote
activation in the absence of ligand (Figure 1C). Such Phe-Phe
stacking interactions in regulatory domains were shown to play a
role in the regulation of catalysis of c-Src [24] and ZAP-70 kinases
[25].
We have previously shown that mutation of V617 to Ala does
not support constitutive activation of JAK2 [26]. In order to
further investigate the effect of the predicted contact between F595
and F617, we mutated the Phe at position 595 of murine JAK2 to
several different amino acids in the context of V617F, and tested
the activity of the double mutants in luciferase assays by
quantifying the STAT5 trancriptional activity induced by each
mutant in transient transfections in the JAK2-deficient fibrosar-
coma cell line, c-2A [27]. As the c-2A cell line does not express
any endogenous JAK2, the activity levels we elicited were due
solely to our transfected mutants. We observed up to an 85%
decrease in the constitutive activity of JAK2 V617F, depending on
the particular amino acid substitution at position 595 (Figure 2A).
Mutation of F595 to Lys elicited the highest decrease in JAK2
V617F constitutive activity, followed by Ala, Val and Ile.
Contrarily, mutation of F595 to Tyr or Trp, supported a level of
constitutive activity of V617F similar to non-mutated F595,
indicating the presence of an aromatic residue at position 595 is
required to maintain the constitutive activity of JAK2 V617F
(Figure 2A).
Next, we asked whether mutation of the F595 residue to Ala,
Lys, Val or Ile critically influenced the ability of wild-type JAK2 or
of JAK2 V617F to respond to Epo-activated EpoR. As depicted in
Figure 2B, F595 mutations generally do not impair activation by
Epo. The F595I mutant responds to Epo indistinguishably from
JAK2 wild-type. Mutants F595A and F595V exhibit a small
inhibition to high Epo doses (Figure 2B), while in the V617F
context these mutants do not affect Epo response (Figure 2C). The
F595K mutants in contrast, appear to reduce Epo activation of
JAK2 V617F to a certain degree (data not shown). Importantly,
the single mutations at F595 did not induce constitutive activation
of JAK2 (Figure 2B). Taken together, our results indicate that helix
C residue F595 is critical for constitutive activation of JAK2
signaling by V617F, and that the nature of the amino acid
substitution at F595 can alter the full response to ligand but is not
required for initiation of activation of JAK2 in response to
cytokine receptor activation.
Interestingly, mutating the beginning segment of the JH2 aC
helix did not have the same effect on the constitutive activity of
JAK2 V617F as mutating F595. We introduced a R588A/E592A
mutation in JAK2 V617F and observed no significant decrease in
STAT5 transcriptional activity relative to the nonmutated protein,
unless F595A was additionally introduced (Figure S1). Assuming a
regular alpha helical pattern for the JH2 aC helix, residues 588
and 592 would be located on the same face of the helix as F595,
each on one of the preceding turns. The fact that they do not alter
the constitutive activity of JAK V617F suggests that F595 plays a
specific role in supporting activation by the V617F mutation.
Functional studies of the F595A mutation on the
proliferation and transformation of Ba/F3 cells stably
expressing JAK2 F595A/V617F
We subsequently investigated the effect of the F595 substitution
on the constitutive activity of JAK2 V617F, in stably-expressing
Ba/F3 cells and compared its activity level to the V617F single
mutant and to wild-type. Ba/F3 are murine bone-marrow derived
proB cells which depend on interleukin-3 (IL-3) for proliferation.
Withdrawal of IL-3 leads to cell death, unless JAK2 V617F is
expressed. We chose the F595 to Ala mutation as it induced a
large decrease in the constitutive activity of V617F (Figure 2A).
293T-derived BOSC cells were used to produce retroviral
supernatants of the JAK2 mutants cloned into the bicistronic
vector pMX-IRES-GFP. Ba/F3 cells expressing the murine EpoR
were infected with the supernatants and sorted for similar GFP
levels 72 hours later. The sorted cells stably expressing each JAK2
mutant were washed and their proliferation in growth factor-free
medium was followed for 7 days. Parental Ba/F3-EpoR cells and
the sorted cells expressing JAK2 wild-type or JAK2 F595A were
not able to support constitutive proliferation in this minimal
medium, but could grow in the presence of Epo (data not shown),
while JAK2 V617F-expressing cells proliferated at a very high rate
in the absence of any growth factors (Figure 3A). The cells
expressing JAK2 F595A/V617F lost most of their proliferative
advantage, consistent with the presence of F595 being key to the
preservation of constitutive activity (Figure 3A). As an additional
control, we included Ba/F3-EpoR cells expressing JAK2 F595W/
V617F, a mutant which maintained a level of constitutive activity
almost identical to V617F in luciferase assays (Figure 2A). As
expected, the JAK2 F595W/V617F mutant could also support
autonomous growth of sorted Ba/F3-EpoR cells to a level identical
to V617F (Figure 3A), pointing to an aromaticity requirement at
position 595 playing a role in the constitutive activity of V617F.
JAK2V617F Activation by F595
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and F595A/V617F were separately washed, incubated without
serum and cytokines overnight (starvation) and electroporated with
pGRR5-Luc and pRLTK-Luc reporters the next day. The STAT5
transcriptional activity induced by each mutant was measured two
hours later. Similar to the c-2A cells (Figure 2A), we observed a
marked decrease in STAT5 transcriptional activity of the sorted
Ba/F3-EpoR cells expressing the F595A/V617F mutant as
compared to cells expressing V617F alone (Figure 3B). Ba/F3-
EpoR cells expressing JAK2wild-type displayed a lowactivity in the
absence of ligand, but responded well upon stimutation with 50 U/
ml Epo (Figure 3B). As an additional positive control, we included
Figure 1. Sequence homology and distances between homologous JAK2 V617 and F595 positions in other kinases and a model of
the relative positions of the two residues in JAK2. (A) Alignment of part of the pseudokinase domain of JAK2 with other kinases containing a
GVCV-like motif. (B) Distances between the nearest atoms of homologous F595 and V617 residues in the other kinases. Distances were estimated
based on the PDB coordinates with UCSF Chimera program [46]. (C) Predicted relative position of the JAK2 JH1 and JH2 aC helices based on the
homology model of Lindauer et al [19]. In this predicted arrangement, residue F595 in the JH2 aC helix is in the proximity of mutated V617F residue,
also located in the pseudokinase domain.
doi:10.1371/journal.pone.0011157.g001
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autonomous growth. As expected, these cells induced a constitutive
STAT5 activation in the absence of cytokines almost double that
induced by their sorted counterparts (Figure 3B).
Lastly,the sorted Ba/F3-EpoR cells expressing each mutant were
stimulated or not with Epo, lysed and immunobloted in the
presence of phosphospecific antibodies (Figure 3C). When compar-
ing the pJAK2 and pSTAT5 levels in the total lysates, we were able
to detect pJAK2 and pSTAT5 activities for V617F, in the absence
of Epo stimulation.Thisactivation was absent in the cells expressing
JAK2 wild-type and JAK2 F595A/V617F, but could be detected to
a lower degree in the cells expressing JAK2 F595W/V617F,
consistent with the proliferation data (Figure 3A) and the transient
transfection luciferase assay (Figure 2A). As expected, all mutants
displayed strong pSTAT5 and pJAK2 activation upon Epo
stimulation (Figure 3C). We also investigated how signaling via
the Erk pathway was affected by the F595 mutations and detected
that pErk1/2 levels were elevated in nonstimulated sorted cells
expressing JAK2 V617F, but decreased once F595A mutation was
additionally introduced. However, substitution of F595 to Trp,
restored the autonomous pErk1/2 signaling (Figure 3C). Taken
together, these results indicated that a Phe, or at least another
aromatic residue, was required at position 595 to support JAK2
V617F constitutive signaling via the STAT and Erk pathways.
Pseudokinase domain aC helix residue F595 is also
required for constitutive activation of the exon 12 JAK2
K539L mutant and the JAK2 mutants T875N and R683G
We next asked the question whether the integrity of F595 also
plays a role in the constitutive activity of other previously-
described JAK2 mutants. In 3% of PV patients where the V617F
mutation is not present, four somatic gain-of-function mutations in
exon 12 of JAK2 have been reported, out of which JAK2 K539L,
located in the linker region between the SH2 and JH2 domains,
was the most common [28]. Another point mutation first identified
in a megakaryoblastic cell line derived from an acute megakar-
yoblastic leukemia (AMKL) patient, and subsequently detected in
a screen of human AMKL cell lines for STAT5 activation,
presented a T875N substitution in the kinase domain of JAK2
[29]. The JAK2 R683G mutation located in the hinge region
between N-terminal and C-terminal lobes of the pseudokinase
domain, was identified in a screen of pediatric acute lymphoblastic
leukemia (ALL) patient samples [30]. JAK2 K539L, T875N and
R683G were shown to exhibit constitutive STAT5 activation and
to transform Ba/F3 cells expressing the EpoR to cytokine-
independence [28,29,30].
We introduced the F595A mutation individually in the context
of JAK2 K539L, JAK2 T875N and JAK2 R683G and studied its
effect on the activity of each mutant by quantifying the STAT5
levels in a luciferase assay of transiently transfected c-2A cells. In
all three mutants, JAK2 K539L, T875N and R683G, and similar
to JAK2 V617F, the STAT5 activity was strongly inhibited by the
presence of the F595A mutation (Figure 4A), indicating that F595
is also required for constitutive activation of these JAK2 mutants.
The signaling effects of the F595A mutation were also examined
in sorted Ba/F3-EpoR cells expressing JAK2 K539L/F595A,
JAK2 T875N/F595A and JAK2 R683G/F595A. Cells were
washed and maintained in medium free of growth factors for 7
days. We observed that Ba/F3-EpoR cells expressing JAK2
V617F, JAK2 K539L, JAK2 T875N and JAK2 R683G could
proliferate in this medium, while the same mutants with the
additional F595A mutation lost most of their autonomous growth
(Figure 4B). In the case of JAK2 K539L/F595A, the presence of
the F595A mutation induced a decrease in the initial proliferation
rate, but by day 7, these cells had regained the same proliferation
ability as JAK2 K539L (Figure 4B). These results suggested that
residue F595 is also important in the constitutive signaling of JAK2
T875N and JAK2 R683G and initially to JAK2 K539L, implying
that activation of catalysis by JAK mutations may be mediated by
conformational changes in the JH2 aC helix.
Based on its predicted location, the K539L mutation may affect
the conformation of the upper V617 loop which would in turn
interact with F595 and induce a rotation or conformational
change in the JH2 aC helix triggering constitutive activity
(Figure 4C, left panel). In the absence of F595 (i.e. F595A), it is
tempting to speculate that the loop-helix interaction may be
altered, decreasing constitutive activity. R683G may increase the
flexibility of the linker region between the two lobes of the
pseudokinase domain [30] and in doing so could require a certain
conformation of the JH2 aC, which is lost when F595A is present.
T875N is located in the kinase domain of JAK2, in a loop
predicted to be within interaction distance of the linker region
between the kinase and pseudokinase domains (Figure 4C, right
panel) and could induce constitutive activity of JAK2 by triggering
a conformational change of the pseudokinase domain. Crosstalk
between the aC helices of JH1 and JH2 may be necessary for this,
and introducing the F595A mutation could potentially alter the
local conformation of the JH2 aC, hindering this helix-helix
communication.
The JAK1 helix C residue F636 is also required for
constitutive activity of JAK1 V658F
We have previously shown that the JAK2 V617F homologous
mutation in JAK1, V658F, induces constitutive activation of JAK1
[31]. Recently the JAK1 V658F mutation was also identified from
a screen of acute leukemia patients [32]. We now investigated
whether the F595 homologous residue in JAK1, F636, also plays a
role in the constitutive activation of this kinase, in a similar manner
to JAK2. We substituted JAK1 residue F636 to Ala in the context
of V658F, and quantified the STAT3 activity of this mutant in the
JAK1-deficient cell line, U4C. As can be seen in Figure 5,
substitution of F636 to Ala induces a large decrease in the
constitutive activity of JAK1 V658F, indicating that the necessity
of F636 is maintained in JAK1, similar to JAK2. This similar
requirement of an intact F636 further points to the possibility that
our data might also be relevant for JAK1 mutations recently
identified in T-cell adult lymphoblastic leukemia (T-ALL) [32,33].
Orientation of the dimeric EpoR is essential for activation
of JAK2 wild-type, but not for V617F
Given that JAKs are appended to the cytoplasmic domains of
cytokine receptors, the hypothesis that V617F can induce
Figure 2. Effect of the substitution of residue F595 in the JH2 aC helix on the constitutive activity of JAK2 V617F and on the ligand-
induced activation of JAK2 wild-type measured by luciferase assays. (A) Mutation of F595 to some residues induces up to an 86% decrease in
the constitutive activity of JAK2 V617F, depending on the particular substitution, while mutation of F595 to aromatic residues rescues the constitutive
activity ofJAK2V617F.Theactivity ofwild-type JAK2andofJAK2 F595Aweresimilar andamounted to15-20%oftheactivityofJAK2 V617F(notshown).
(B) The single substitution mutants at position 595 display Epo responses similar to JAK2 wild-type at various concentrations of Epo and do not induce
constitutive activation of JAK2 wild-type. (C) The JAK2 F595X/V617F double mutants also respond to Epo in a manner analogous to JAK2 wild-type.
doi:10.1371/journal.pone.0011157.g002
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interaction with the JH2 aC helix which triggers catalytic activity,
has one immediate implication. That is, JAK2 V617F can
overcome the requirement for a ligand-induced conformational
change and effectively be capable of signaling from various relative
conformations of a dimeric cytokine receptor, while in the wild-
type scenario a ligand-induced conformational change in the
receptor transmembrane and cytoplasmic domains is required,
leading to the proper active conformation.
In order to test whether this implication holds true, we
employed a system we previously used to determine the active
orientations of the transmembrane and cytosolic domains of the
Epo receptor [34]. Briefly, the extracellular domain of EpoR was
replaced with a dimeric coiled-coil and by varying the junction
between the coiled coil and transmembrane domain, all seven
possible conformations were imposed on the TM-cytosolic
domains of EpoR (Figure 6A) [34]. The predictions of dimeric
orientation were confirmed by cysteine-scanning mutagenesis of
the transmembrane domain of EpoR in fusion with the Put3 coiled
coil [35]. Using this system, we identified two conformations
corresponding to an activated EpoR dimer (denoted cc-EpoR-III
and cc-EpoR-VI) and two corresponding to an inactive EpoR
dimer (denoted cc-EpoR-II and cc-EpoR-V) (Figure 6A) [34].
We now co-expressed these previously engineered active and
inactive coiled-coil EpoR constructs with either JAK2 wild-type or
V617F, along with STAT5, pGRR5-Luc and pRLTK-Luc
reporters, and measured their STAT5 transcriptional activities in
luciferase assays in c-2A cells. We observed that, as expected,
JAK2 wild-type signals best from the two conformations
corresponding to an active EpoR dimer (III and VI) (Figure 6B).
On other hand, consistent with our hypothesis, we observed that
V617F was able to signal relatively well from both active (III and
VI) and inactive (II and V) dimeric conformation (Figure 6B). This
is in line with reports showing that presence of a dimeric receptor,
like EpoR, supports constitutive activation of JAK2 V617F
[36,37].
We then compared the activities of two F595 mutants which
decreased JAK2 V617F constitutive activity, F595A/V617F and
F595V/V617F (Figure 2A) with V617F and wild-type in the same
assay. We noticed that substituting the Phe at position 595, causes
the F595A/V617F and F595V/V617F mutants to lose their ability
to signal from both active and inactive dimeric conformations and
to prefer the conformations corresponding to an activated EpoR
dimer, similar to JAK2 wild-type (III and VI) (Figure 6B).
Discussion
Our main observation is that residue F595, residing in the
middle of the pseudokinase domain aC helix, plays a key role in
the constitutive activation of JAK2 V617F. At the same time, the
integrity of F595 was also key to several other JAK2 mutants
located in different locations of the protein, JAK2 K539L, JAK2
T875N and JAK2 R683G. We present evidence that residue F595
is not crucial for the mechanism of ligand-induced JAK2
activation, as shown by the signaling abilities of the F595 single
and double mutants in the presence of various concentrations of
Epo ligand. Also, mutation of F595 to several different residues did
not induce constitutive signaling from wild-type JAK2.
Mutation of F595 to Ala, Val, Ile or Lys in the context of V617F
drastically decreased the constitutive activity of the V617F mutant
in both the JAK2-deficient c-2A and the hematopoietic Ba/F3 cell
line, in transient and stable expression experiments, respectively.
On the contrary, when F595 was replaced by an aromatic residue
(Tyr or Trp) in the context of V617F, the constitutive activity was
maintained. The substitution of F595 to Ala decreased the
constitutive activity of JAK2 K539L, JAK2 T875N, and also of
JAK2 R683G. Furthermore, constitutive activity of a JAK1
mutant homologous to JAK2 V617F (JAK1 V658F) was also
inhibited by the homologous JAK1 F595 mutation (F636A),
suggesting that our results in JAK2 might be relevant for activation
of JAK1 mutants recently identified in T-ALL [32,33].
A theoretical study was recently published [38], where
molecular dynamics simulations indicated that F595 might be
responsible for maintaining wild-type JAK2 inactive and, as a
consequence, its possible interaction with F617 could alleviate this
inhibition and contribute to activation. One the one hand, we
agree with Lee et al that F595 is crucial for JAK2 V617F activity,
but our results support the contrary notion for the wild-type JAK2,
that is, F595 does not play a major role in the physiologic ligand-
activation of JAK2, or in its inactivity in the basal state (Figures 2B
and 6C). On the other hand, we do support a key role for F595 not
only in the constitutive activity of JAK2 V617F, but also of several
JAK2 oncogenic mutants.
Our data suggest that a specific interaction might occur between
F595 in the JH2 aC helix and F617, predicted to be located in the
loop between b-strands 4 and 5 (Figure 1C) [19]. We acknowledge
that only a crystal structure of a complex of JAK2 JH1 and JH2
domains would decisively establish the presence of this interaction.
In the case of JAK2 V617F, a Phe, Trp or Tyr at position 595 are
able to maintain constitutive activity, suggesting an aromatic
requirement at this position, and pointing to a possible specific
stacking interaction between residues F595 and F617 as the most
productive manner to activate the kinase domain. In the absence
of ligand, such an aromatic initial interaction could induce a
conformational change in the JH2 aC helix and trigger catalytic
activity via repositioning of key catalytic residues. While this might
represent the most efficient path to autoactivation, other, possibly
less efficient paths must exist, that similarly rely on F595, since
other JAK2 V617 mutations are also constitutively active (i.e.
V617M, V617L, V617I [26]), and since the F595A mutation
inhibits their activation (data not shown).
Given this scenario, we expected that when appended to a
dimeric cytokine receptor, JAK2 V617F would signal irrespective
of the particular dimeric orientation of the receptor, and that other
Figure 3. Role of JH2 aC helix residue F595 in the proliferation and activation of Ba/F3 cells stably expressing the Epo receptor and
individual JAK2 mutants. (A) Proliferation assay of sorted Ba/F3-EpoR cells stably expressing each mutant and wild-type, in medium without
growth factors for 7 days. JAK2 V617F is able to proliferate constitutively in this minimal medium starting from the first day (black triangles). The
F595A/V617F double mutant lost most of its proliferative advantage (green stars), while the Ba/F3-EpoR parental cell line, or expressing either wild-
type or F595A alone could not proliferate in the absence of growth factors. Substitution of F595 to an aromatic residue (F595W) restored autonomous
growth (red circles). (B) Luciferase assay in sorted Ba/F3 cells stably expressing the Epo receptor and each individual JAK2 mutant or wild-type. Each
cell line was individually electroporated with the pGRR5-Luc and pRLTK-Luc reporters and the STAT5 transcriptional activity was measured. The Ba/
F3-EpoR cells expressing JAK2 V617F previously selected for autonomous growth show a typical increase in STAT5 transcriptional activity both in the
presence and absence of Epo. (C) Immunoblot analysis of sorted Ba/F3-EpoR cells expressing individual mutants or wild-type, in presence of absence
of Epo stimulation. pJAK2, pSTAT5 and pErk1/2 levels of JAK2 V617F, probed with specific antibodies revealed a constitutive signal in the absence of
stimulation. This signal was absent in the cells expressing F595A/V617F but partially rescued in cells expressing F595W/V617F.
doi:10.1371/journal.pone.0011157.g003
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PLoS ONE | www.plosone.org 7 June 2010 | Volume 5 | Issue 6 | e11157Figure 4. Substitution of F595 to Ala has an inhibitory effect on the constitutive activity of other JAK2 oncogenic mutants. (A) JAK2
K539L, T875N and R683G all induce constitutive activation of JAK2, however all three mutants display a marked decrease in STAT5 transcriptional
activity in c-2A cells when the F595A mutation is also introduced. (B) Proliferation assay of sorted Ba/F3-EpoR cells stably expressing each constitutive
mutant and wild-type, in medium without growth factors for 7 days. Cells expressing JAK2 V617F (black triangles), K539L (blue lines), T875N (green
stars) and R683G (yellow circles) can proliferate constitutively in this minimal medium starting from the first day. Substitution of F595 to Ala
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PLoS ONE | www.plosone.org 8 June 2010 | Volume 5 | Issue 6 | e11157less active mutants (V617M, V617L, V617I) might still depend on
a conformational change of a dimeric receptor. This was indeed
the case. When co-expressed with both active and inactive EpoR
dimers, JAK2 V617F was able to induce a constitutive signal,
regardless of the relative dimeric conformation (Figure 6B). JAK2
mutants V617I, V617L or V617M could signal from both inactive
and active cc-EpoR dimer conformations, but they signaled
stronger from active cc-EpoR dimers (data not shown). JAK2 wild-
type, on the other hand, was activated only in the presence of the
particular conformations corresponding to an activated EpoR
dimer. Taken together, these data indicate that the F617: F595
pair is optimal for constitutive activation, irrespective of receptor
conformation, but that other bulky aliphatic residues at 617 can
induce constitutive activation of JAK2 via F595, with the caveat
that such mutants might additionally require a conformational
change of the scaffold receptor, in this case EpoR. In any case,
F595 is pivotal for initiating autoactivation of JAK2, while it is not
crucial for cytokine-induced JAK2 activation. In the wild-type
scenario, a large conformational change of the receptor, that
involves rotation [34] and a scissors-like movement [39], brings
about kinase domain activation (model, Figure 6C).
Our data also provide evidence that pseudokinase domains
might be pivotal to triggering kinase domain activation, even when
mutations are not located in the proximity of pseudokinase
domain residue V617, as is the case with JAK2 K539L (SH2-JH2
linker), JAK2 T875N (JH1) and JAK2 R683G (hinge of JH2)
(Figure 4C). That pseudokinase domains appear in certain
proteins to assume ‘‘active’’ conformations [40,41] suggests that
they evolved roles in transmission of conformational changes, and
thus could be targets for inhibitors.
Several JAK2 kinase domain inhibitors, that are ATP-binding
competitors are in clinical trials for primary or secondary
myelofibrosis [42,43]. These inhibitors do not discriminate
between wild-type and mutant JAK2, and can induce unwanted
effects, such as anemia and thrombocytopenia. An ideal inhibitor
for patients harboring JAK mutants would have to preferentially
target the mutant JAK and spare signaling by the wild-type JAK.
We suggest that the region in the middle of the pseudokinase
domain helix C around residue F595 could be the target of such a
specific inhibitor.
Materials and Methods
JAK2 mutant plasmid constructs
All murine JAK2 (and JAK1) mutants were obtained by PCR
reactions with mutagenic complementary forward and reverse
primers by the QuickChange Site-Directed Mutagenesis method
(Stratagene). All constructs were cloned into the bicistronic
retroviral vector pMX-IRES-GFP and verified by sequencing. In
most cases, 2 independent clones were tested per each mutant.
Cell lines and retroviral transductions
c-2A and U4C are JAK2-deficient and JAK1-deficient human
fibrosarcoma cells [27,44]. Ba/F3-EpoR cells are murine IL-3-
dependent cells that are expressing the murine erythropoietin
receptor. Wild-type and mutant JAKs were transfected into BOSC
packaging cells to produce retroviruses which were subsequently
used to infect Ba/F3-EpoR cells as described [34]. GFP positive
cells were sorted by FACS 72 hours after infection, washed and
cultured in the absence of cytokines in RPMI medium + 10% FBS.
Cell numbers were recorded over a period of seven days with a
Coulter cell counter. The V617F mutant which acquired the
ability to proliferate in the absence of cytokines was further
cultured in RPMI medium + 10% FBS. The sorted Ba/F3-EpoR
individually in the context of each active mutant causes a marked decrease in autonomous growth. The JAK2 K539L/F595A mutant (red lines) lost
most of its proliferative advantage during the first 4 days, but by day 7 had regained the same level of autonomous growth as its single counterpart
(blue lines). (C) Predicted locations (red spheres) of mutants K539L, R683G, V617F (left panel) and T875N (right panel) within the model structure of
JAK2, based on coordinates of the homology model proposed by Lindauer et al [19]. The right panel is rotated 180u relative to the left panel. The
kinase domain is depicted in yellow and the pseudokinase domain in blue. The location of F595 is shown as a green sphere. Circular arrows placed
between helices C of JH2 and JH1 indicate potential conformational changes originating in JH2 and transmitted to JH1. Solid double-headed arrow
placed near the R683G mutation suggests increased flexibility induced by this JH2 hinge mutant. Green star (right panel) suggests T875N mutation
changes JH1-JH2 linker segment conformation, which is transmitted to JH2 helix C F595.
doi:10.1371/journal.pone.0011157.g004
Figure 5. The F595A homolog in JAK1, F636A, blocks constitutive activity of JAK1 V658F. Transient transfection in the JAK1-deficient U4C
cell line indicates a decrease in the STAT3 transcriptional activity in the JAK1 F636A/V658F, as compared to JAK1 V658F.
doi:10.1371/journal.pone.0011157.g005
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PLoS ONE | www.plosone.org 10 June 2010 | Volume 5 | Issue 6 | e11157cells expressing the JAK2 mutants or wild-type were maintained in
RPMI medium + 10% fetal bovine serum and WEHI cell
supernatant, as a source of IL-3.
Dual luciferase assays
The STAT5 transcriptional activity of the various mutants was
measured in c-2A cells (fibrosarcoma cells deficient in JAK2) by
dual luciferase assays with the STAT reporter, pGRR5-Luc [45].
Cells were seeded in 24-well plates overnight and transfected using
lipofectamine, with pGRR5-Luc, STAT5, EpoR, the cDNA
coding for each individual JAK mutant and pRLTK-Luc as an
internal control. The STAT3 transcriptional activity of JAK1
mutants was measured in JAK1-deficient U4C cells [44] by
transiently transfecting each JAK1 construct, the pGRR5-Luc and
pRLTK-Luc reporters and the interleukin-9 receptor (IL-9R).
Medium was changed 4 hours after transfection and stimulation
with Epo was performed when stated. The cells were lysed
24 hours after transfection and luminescence was recorded on a
TD-20/20 or Glomax 96-well plate luminometer. When perform-
ing the assay on stably transduced sorted Ba/F3-EpoR cells
(expressing each JAK2 mutant), cells were starved overnight in
RPMI medium with 1 mg/ml BSA, next day stimulated or not
with 50 U/ml Epo and electroporated with the pGRR5-Luc and
pRLTK-Luc luciferase reporters. The cells were subsequently
cultured for 2 hours, lysed in 100 ml 1X passive lysis buffer and
their luminescence was recorded.
Immunoblotting
2.5610
7 Ba/F3-EpoR cells expressing each JAK2 mutant were
starved overnight in RPMI medium with 1 mg/ml BSA, and
stimulated or not with 50 U/ml Epo for 15 minutes. Cells were
resuspended in cold lysis buffer (1%NP40 + 1X Protease Inhibitor
Cocktail (Roche), 1 mM vanadate, 1 mM PMSF). Upon incubation
on ice for 30 minutes and spinning for 20 minutes at 20,000 g and
4uC, the supernatant was mixed with an appropriate volume of 2X
Laemmli, boiled and 40 mg total protein was loaded on NuPage 4–
12% Bis-Tris gels (Invitrogen). Transfer on nitrocellulose membranes
was carried out with the iBlot
TM Dry Blotting System (Invitrogen).
Western blotting antibodies were directed against: phospho-
JAK2 (Millipore), JAK2 (Santa Cruz), beta-actin (Sigma), and
phospho-STAT5 A/B (Tyr694), phospho-Erk1/2 (Tyr202/
Tyr204), Erk1/2 (Cell Signaling Technology).
Structural modeling
The coordinates for the homology model of JAK2 in an inactive
conformation were obtained from Dr. Romano Kroemer. PDB
coordinates for JAK2 JH1 active structure were obtained from the
PDB database (Accession codes 2B7A, 3FUP). All other PDB
coordinates were obtained from the PDB database as described in
each case. Molecular graphics images were produced using the
UCSF Chimera package from the Resource for Biocomputing,
Visualization, and Informatics at the University of California, San
Francisco (supported by NIH P41 RR-01081) [46].
Supporting Information
Figure S1 Mutations in the beginning segment of the JH2 aC
helix do not alter the constitutive activity of JAK2 V617F.
Substitution of JH2 helix C residues R588 and E592 simulta-
neously to Ala has no effect on the STAT5 transcriptional activity
of JAK2 V617F (or JAK2 wild-type as a control), unless F595 is
also mutated.
Found at: doi:10.1371/journal.pone.0011157.s001 (0.06 MB TIF)
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